In the metastatic setting, targeted therapy with BRAF and MEK inhibitors (BRAFi, MEKi) approved for BRAF-mutant tumors, and immunotherapy with inhibitors of immune checkpoints, approved for both BRAF-mutant and BRAF wild-type melanomas, have significantly increased objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) of patients with respect to dacarbazine chemotherapy [2, 3]. This evidence concerns the gene MAP2K7 and melanoma.